Home

GeoVax Labs, Inc. - Common Stock (GOVX)

1.7400
0.00 (0.00%)

Geovax Labs is a biotechnology company that focuses on developing innovative vaccines and immunotherapies for infectious diseases and cancer

With a particular emphasis on addressing public health concerns, Geovax leverages its proprietary technology platform to create novel medical solutions aimed at enhancing immune responses. The company is involved in various stages of research and development, working to advance its projects through clinical trials and collaborations with other research entities, committed to improving health outcomes and combating significant health threats.

SummaryNewsPress ReleasesChartHistoricalFAQ
Previous Close1.740
Open1.760
Bid1.720
Ask1.730
Day's Range1.691 - 1.820
52 Week Range1.090 - 11.18
Volume2,041,065
Market Cap3.78M
PE Ratio (TTM)-0.7768
EPS (TTM)-2.2
Dividend & YieldN/A (N/A)
1 Month Average Volume568,451

News & Press Releases

GeoVax Anticipates Significant 2025 Progress With Catalyst-Rich Milestones Across Key Programs
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · February 5, 2025
GeoVax Anticipates Significant 2025 Progress With Catalyst-Rich Milestones Across Key Programs
Strategic Progress Across COVID-19, Mpox, Oncology Therapies and AI Integration Positions GeoVax for Strong Momentum
Via TheNewswire.com · February 5, 2025
GeoVax to Showcase Advancements in Vaccines & Immunotherapies at the 2025 BIO CEO & Investor Conference
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · February 4, 2025
GeoVax to Showcase Advancements in Vaccines & Immunotherapies at the 2025 BIO CEO & Investor Conference
ATLANTA, GA - February 4, 2025 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, announced today that its Chairman and CEO, David Dodd, will present GeoVax’s 2025 strategic vision and milestones at the 2025 BIO CEO & Investor Conference, taking place in-person in New York, NY on February 10-12, 2025.
Via TheNewswire.com · February 4, 2025
GeoVax Announces Strategic Integration of AI in Support of President Trump's Stargate Initiative
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · February 3, 2025
Strengthening America's Biosecurity: GeoVax Advances Domestic Vaccine Capability
Addressing Critical U.S. Vulnerabilities in Vaccine Supply and National Preparedness
Via TheNewswire.com · January 29, 2025
GeoVax Announces Major Gedeptin Milestone With Plans of Phase 2 Trial
Represents a Key Step Toward Validating Gedeptin Potential in Solid Tumor Therapy
Via TheNewswire.com · January 15, 2025
GeoVax Announces Strategic Integration of AI in Support of President Trump's Stargate Initiative
Harnessing AI to Revolutionize Vaccine and Therapy Development
Via TheNewswire.com · February 3, 2025
Strengthening America's Biosecurity: GeoVax Advances Domestic Vaccine Capability
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · January 29, 2025
GeoVax Advanced MVA Manufacturing Process: Aimed to Enhance Vaccine Supply Worldwide
Process Expected to Increase Production Yield, Flexibility at Lower Cost
Via TheNewswire.com · January 27, 2025
GeoVax Advanced MVA Manufacturing Process: Aimed to Enhance Vaccine Supply Worldwide
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · January 27, 2025
GeoVax Announces Major Gedeptin Milestone With Plans of Phase 2 Trial
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · January 15, 2025
Earnings Scheduled For November 12, 2024benzinga.com
Via Benzinga · November 12, 2024
Earnings Preview: Geovax Labsbenzinga.com
Via Benzinga · November 11, 2024
GeoVax Achieves Significant Progress in Next-Generation COVID-19 Vaccine Development Throughout 2024
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · January 13, 2025
GeoVax Achieves Significant Progress in Next-Generation COVID-19 Vaccine Development Throughout 2024
Advancements Position GEO-CM04S1 as a Leading Vaccine Candidate Addressing Unmet Medical Needs, Especially Among Immunocompromised Patients
Via TheNewswire.com · January 13, 2025
GeoVax to Review 2024 Progress at the Emerging Growth Conference on January 16, 2025
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · January 8, 2025
GeoVax to Review 2024 Progress at the Emerging Growth Conference on January 16, 2025
Company to provide updates on progress toward the BARDA-funded Phase 2b trial of GEO-CM04S1, its next-generation COVID-19 vaccine as well as for Gedeptin® (solid tumor therapy) and GEO-MVA (Mpox/Smallpox vaccine)
Via TheNewswire.com · January 8, 2025
GeoVax to Review 2024 Progress at Biotech Showcase During J.P. Morgan Healthcare Week 2025
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · January 6, 2025
GeoVax to Review 2024 Progress at Biotech Showcase During J.P. Morgan Healthcare Week 2025
ATLANTA, GA - January 6, 2025 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that David Dodd, Chief Executive Officer, will review 2024 progress in a presentation at the Biotech Showcase coinciding with the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, January 13-16, 2025.
Via TheNewswire.com · January 6, 2025
3 Penny Stocks Ready to Break Out in 2025
Vuzix, GeoVox Labs, and Cardiol Therapeutics emerged as notable penny stocks late in 2024 for their potential to scale operations and launch new products.
Via MarketBeat · November 29, 2024
12 Health Care Stocks Moving In Wednesday's Pre-Market Sessionbenzinga.com
Via Benzinga · November 13, 2024
This GeoVax Labs Analyst Begins Coverage On A Bullish Note; Here Are Top Initiations For Mondaybenzinga.com
Via Benzinga · November 11, 2024
David Dodd, CEO of GeoVax Labs Inc. (NASDAQ: GOVX), to Present at NobleCon20
In the dynamic field of biotechnology, GeoVax Labs (NASDAQGOVX) is at the forefront of developing innovative vaccine therapies. The company will be presenting alongside world-class headliners such as Zack Kass, former Head of Go-To-Market at OpenAI where ChatGPT was created, and “Shark Tank” stars Kevin O’Leary, Robert Herjavec, and Daymond John.
Via Investor Brand Network · November 6, 2024
EXCLUSIVE: Top 20 Most-Searched Tickers On Benzinga Pro In September 2024 – Where Do Tesla, Nvidia, Apple, DJT Stock Rank?benzinga.com
A look at the 20 most searched tickers on Benzinga Pro, which includes many familiar names and some penny stocks that may be less familiar.
Via Benzinga · October 2, 2024